Interprotein Corporation

http://www.interprotein.com/

 Interprotein is a biopharmaceutical company engages in discovering and developing of modulators targeting Protein-Protein Interactions. The company has two proprietary platform technologies: 1)  the deNovo small molecular design technology called "INTENDD" and the conformationally-constrained helix-loop-helix peptide technology called "HLHP".  The company has entered in collaboration agreements with Ipsen, Ajinomoto Pharmaceuticals, Takeda and RaQualia.

 

CellGentech, Inc.

http://www.cellgentech.com/

CellGentech is a biopharmaceutical company developing novel gene-based therapeutics, which use patent-protected technology incorporating cultured adipocytes for ex vivo gene transfection. The company's development pipeline includes novel gene therapy products for enzyme deficiency diseases and new insulin supplement therapy for severe diabetic patients.

Anaeropharma Science Inc.
http://www.anaeropharma.co.jp/
Anaeropharma Science is a clinical-stage biopharmaceutical company developing novel cancer drugs based on the proprietary drug delivery technology using anaerobic bacteria. The company is primarily focused on the tumor specific enzyme/pro-drug therapy by using the genetically engineered Bifidobacterium longum . APS001F has entered phase I/II trials in the United States. Eisai Co. has entered in collboration with Anaeropharma. The company was founded by three professors of Medical School, Shinshu University in 2004.

Kinopharma Inc.
http://www.kinopharma.com/
Kinopharma is a biopharmaceutical company engages in the discovery and development of small molecule drugs for Ser/Thr kinases based on the proprietary platform technologies. The company focuses on two therapeutic areas:
Viral infections  -  Kinopharma targets host kinases which viruses make use of for their own replication. RKP00156 is a potent antiviral agent against HSV, VZV, CMV, HPV, and adenovirus. The clinical study for warts caused by HPV is planned to start under the collaboration with the Kyoto University.
CNS Disorders  -  Kinopharma has conceived the therapeutic ideas from the correlation between Down syndrome and Alzheimer's diseases. The company's DYRK1A inhibitors target hyperphosphorylated tau protein.
KinoPharma has been granted JST research funds.